DefenAge Skincare announced a new skin regeneration technology with the acquisition of a new patent using a regenerative approach for skin care and wound healing. The company says the cutting-edge technology is now available for licensing and product development partnerships, presenting an unparalleled opportunity for innovation in the skincare and pharmaceutical industries.
The new patent is titled “Compositions and Methods to Improve Skin Quality and Appearance, Cure Skin, and Tissue Damage, and Use in Therapy.”
This latest technology expands DefenAge’s portfolio, introducing a second suite of innovations distinct from its renowned Defensin-molecule range. It’s designed to tackle skin anti-aging and wound healing, making it perfect for cosmetic and pharmaceutical applications.
It involved stem cell-derived conditioned media designed to address age-related skin changes by reducing wrinkles, skin laxity, and fine lines, reconstructing skin collagen, and improving skin elasticity, and facilitate and accelerate wound healing, treat burns, and repair other tissue damage.
The patented process unveils a novel method for preparing active ingredients using conditioned media from various stem cells, including pluripotent, induced pluripotent, germ-derived, adult, mesenchymal, neural, progenitor, and skin progenitor cells.
“We are beyond excited to receive this patent from the US Patent Office, especially in the highly competitive and densely patented field of cosmeceuticals utilizing conditioned medium and exosomes,” Nikolay Turovets, Ph.D., primary inventor and CEO of DefenAge, said. “This new technology is poised to be a game-changer, serving as the foundation for standalone products or enhancing exosome-based formulations.”
